{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:24Z","timestamp":1786119624452,"version":"build-2736575974"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/gme.0b013e3181fa264c","type":"journal-article","created":{"date-parts":[[2010,10,23]],"date-time":"2010-10-23T01:43:36Z","timestamp":1287798216000},"page":"1099-1103","source":"Crossref","is-referenced-by-count":6,"title":["Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance"],"prefix":"10.1097","volume":"17","author":[{"given":"Alfred O.","family":"Mueck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0378-5122(91)90193-T","article-title":"Estrogen replacement therapy is not conducive of venous thromboembolism.","volume":"13","author":"Young","year":"1991","journal-title":"Maturitas"},{"key":"R2-4-20210227","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/0002-9378(93)90435-L","article-title":"Thrombosis and hormone replacement therapy in postmenopausal women.","volume":"169","author":"Saleh","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"R3-4-20210227","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(96)07114-0","article-title":"Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.","volume":"348","author":"Jick","year":"1996","journal-title":"Lancet"},{"key":"R4-4-20210227","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(96)07113-9","article-title":"Risk of venous thromboembolism in users of hormone replacement therapy.","volume":"348","author":"Daly","year":"1996","journal-title":"Lancet"},{"key":"R5-4-20210227","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bmj.314.7083.796","article-title":"Hormone replacement therapy and the risk of venous thromboembolism: population-based case-control study.","volume":"314","author":"Perez Gutthann","year":"1997","journal-title":"Br Med J"},{"key":"R6-4-20210227","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-132-9-200005020-00002","article-title":"D, Wenger NK, Herrington D, et al; for the Heart and Estrogen\/Progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen\/Progestin Replacement Study.","volume":"132","year":"2000","journal-title":"Ann Intern Med"},{"key":"R7-4-20210227","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"M, Kuller LH, Prentice R, et al; for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis.","volume":"292","year":"2004","journal-title":"JAMA"},{"key":"R8-4-20210227","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinte.166.7.772","article-title":"Venous thrombosis and conjugated equine estrogen in women without a uterus.","volume":"166","author":"Curb","year":"2006","journal-title":"Arch Intern Med"},{"key":"R9-4-20210227","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R11-4-20210227","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/bmj.39266.425069.AD","article-title":"MR, MacLennan AH, Lawton B, et al; WISDOM group. Main morbidities recorded in the Women's International Study of Long Duration Oestrogen After Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.","volume":"335","year":"2007","journal-title":"BMJ"},{"key":"R12-4-20210227","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"R13-4-20210227","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components.","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"R14-4-20210227","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen.","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"R15-4-20210227","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/humupd\/5.6.721","article-title":"Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks.","volume":"5","author":"Farley","year":"1999","journal-title":"Hum Reprod Update"},{"key":"R16-4-20210227","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(97)00119-4","article-title":"First-time use of newer oral contraceptives and the risk of venous thromboembolism.","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"key":"R17-4-20210227","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/humrep\/14.6.1493","article-title":"The differential risk of oral contraceptives: the impact of full exposure history.","volume":"14","author":"Lewis","year":"1999","journal-title":"Hum Reprod"},{"key":"R18-4-20210227","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives.","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"key":"R19-4-20210227","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0010-7824(98)00033-X","article-title":"Oral contraceptives and venous thromboembolism. A case-control study.","volume":"57","author":"Lidegaard","year":"1998","journal-title":"Contraception"},{"key":"R20-4-20210227","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"R22-4-20210227","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.321.7270.1190","article-title":"Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.","volume":"321","author":"Jick","year":"2000","journal-title":"BMJ"},{"key":"R23-4-20210227","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.321.7259.477","article-title":"Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database.","volume":"321","author":"Farmer","year":"2000","journal-title":"BMJ"},{"key":"R24-4-20210227","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.321.7270.1171","article-title":"Pitfalls of pharmacoepidemiology.","volume":"321","author":"Skegg","year":"2000","journal-title":"BMJ"},{"key":"R25-4-20210227","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.323.7305.119","article-title":"The third generation pill controversy (\"continued\").","volume":"323","author":"Drife","year":"2001","journal-title":"BMJ"},{"key":"R26-4-20210227","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","article-title":"Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.","volume":"90","author":"Dahlback","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-4-20210227","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(05)80081-9","article-title":"Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.","volume":"342","author":"Koster","year":"1993","journal-title":"Lancet"},{"key":"R28-4-20210227","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199402243300801","article-title":"Resistance to activated protein C as a basis for venous thrombosis.","volume":"330","author":"Svensson","year":"1994","journal-title":"N Engl J Med"},{"key":"R29-4-20210227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C.","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"R30-4-20210227","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood"},{"key":"R31-4-20210227","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.","volume":"130","author":"Rodeghiero","year":"1999","journal-title":"Ann Intern Med"},{"key":"R32-4-20210227","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.1997.03540400055031","article-title":"Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.","volume":"277","author":"Ridker","year":"1997","journal-title":"JAMA"},{"key":"R33-4-20210227","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1055\/s-0037-1615887","article-title":"Risk factors for venous thrombotic disease.","volume":"82","author":"Rosendaal","year":"1999","journal-title":"Thromb Haemost"},{"key":"R34-4-20210227","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"R35-4-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.","volume":"97","author":"Rosing","year":"1997","journal-title":"Br J Haematol"},{"key":"R36-4-20210227","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.","volume":"122","author":"Tans","year":"2003","journal-title":"Br J Haematol"},{"key":"R37-4-20210227","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"key":"R38-4-20210227","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(99)80017-8","article-title":"Importance of levonorgestrel dose in oral contraceptives for effects on coagulation.","volume":"354","author":"Kluft","year":"1999","journal-title":"Lancet"},{"key":"R39-4-20210227","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial.","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"key":"R40-4-20210227","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9378(03)00950-5","article-title":"Sex hormone-binding globulin-a surrogate marker for the prothrombotic effects of combined oral contraceptives.","volume":"190","author":"Van Rooijen","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R41-4-20210227","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","article-title":"Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.","volume":"20","author":"van Vliet","year":"2005","journal-title":"Hum Reprod"},{"key":"R42-4-20210227","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/j.1538-7836.2004.00983.x","article-title":"Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.","volume":"2","author":"van Vliet","year":"2004","journal-title":"J Thromb Haemost"},{"key":"R43-4-20210227","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.","volume":"67","year":"2003","journal-title":"Contraception"},{"key":"R44-4-20210227","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1538-7836.2004.00894.x","article-title":"Impact of progestogens on activated protein C (APC) resistance among users of oral contraceptives.","volume":"2","author":"Alhenc-Gelas","year":"2004","journal-title":"J Thromb Haemost"},{"key":"R45-4-20210227","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlind","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R46-4-20210227","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism.","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"R47-4-20210227","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2141.2001.03111.x","article-title":"Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.","volume":"115","author":"Hoibraaten","year":"2001","journal-title":"Br J Haematol"},{"key":"R48-4-20210227","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7326\/0003-4819-135-5-200109040-00008","article-title":"A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.","volume":"135","author":"Middeldorp","year":"2001","journal-title":"Ann Intern Med"},{"key":"R49-4-20210227","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/gme.0b013e3181e102eb","article-title":"Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of the progestogen.","volume":"17","author":"Canonico","year":"2010","journal-title":"Menopause"},{"key":"R50-4-20210227","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613145","article-title":"Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.","volume":"88","author":"Curvers","year":"2002","journal-title":"Thromb Haemost"},{"key":"R51-4-20210227","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/01.ATV.0000074146.36646.C8","article-title":"Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.","volume":"23","author":"Post","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R52-4-20210227","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/01.ATV.0000087141.05044.1F","article-title":"E, Alhenc-Gelas M, Lacut K, et al; SARAH Investigators. Differential effects of oral and transdermal estrogen\/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.","volume":"23","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R53-4-20210227","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"PY, Oger E, Plu-Bureau G; Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"R54-4-20210227","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1538-7836.2010.03839.x","article-title":"Hormone replacement therapy and the risk of venous thromboembolism: a population-based study.","volume":"8","author":"Renoux","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R55-4-20210227","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R56-4-20210227","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"M, Oger E, Plu-Bureau G, et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.","volume":"115","year":"2007","journal-title":"Circulation"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00042192-201017060-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:44:13Z","timestamp":1786041853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201017060-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181fa264c","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}